What do systematic reviews say?

Dopamine agonist vs placebo

• Dopamine agonists for the treatment of cocaine dependence 2015 · Cochrane Headline outcomes only
  no estimate extracted
  4 studies · 202 participants
  Low

Dopamine agonist plus co‐intervention vs co‐intervention

It is very uncertain whether dopamine agonist plus co‐intervention changes multiple pregnancy rate compared with co‐intervention (very low certainty).

• Dopamine agonists for preventing ovarian hyperstimulation syndrome 2021 · Cochrane Headline outcomes only
  OR 2.02 [0.18, 22.77]
  1 study · 166 participants
  Very low

Dopamine agonist plus co‐intervention vs co‐intervention

Dopamine agonist plus co‐intervention showed no clear difference in miscarriage rate compared with co‐intervention (low certainty).

• Dopamine agonists for preventing ovarian hyperstimulation syndrome 2021 · Cochrane Headline outcomes only
  OR 0.65 [0.3, 1.42]
  3 studies · 548 participants
  Low

Dopamine agonist plus co‐intervention vs co‐intervention

It is very uncertain whether dopamine agonist plus co‐intervention changes any other adverse events compared with co‐intervention (very low certainty).

• Dopamine agonists for preventing ovarian hyperstimulation syndrome 2021 · Cochrane Headline outcomes only
  OR 3.03 [0.12, 75.28]
  2 studies · 366 participants
  Very low

Dopamine agonist plus co‐intervention vs co‐intervention

Dopamine agonist plus co‐intervention may leads to lower incidence of moderate or severe OHSS compared with co‐intervention (low certainty).

• Dopamine agonists for preventing ovarian hyperstimulation syndrome 2021 · Cochrane Headline outcomes only
  OR 0.48 [0.28, 0.84]
  4 studies · 748 participants
  Low

Dopamine agonist plus co‐intervention vs co‐intervention

Dopamine agonist plus co‐intervention showed no clear difference in live birth rate compared with co‐intervention (low certainty).

• Dopamine agonists for preventing ovarian hyperstimulation syndrome 2021 · Cochrane Headline outcomes only
  OR 1.21 [0.81, 1.8]
  2 studies · 400 participants
  Low

Dopamine agonist plus co‐intervention vs co‐intervention

Dopamine agonist plus co‐intervention showed no clear difference in clinical pregnancy rate compared with co‐intervention (low certainty).

• Dopamine agonists for preventing ovarian hyperstimulation syndrome 2021 · Cochrane Headline outcomes only
  OR 1.11 [0.83, 1.49]
  4 studies · 748 participants
  Low

Dopamine agonist vs placebo

• Dopamine agonists for the treatment of restless legs syndrome 2011 · Cochrane Headline outcomes only
  no estimate extracted
  30 studies · 6380 participants
  Moderate

Dopamine agonist vs levodopa

Summary of findings: dopamine agonists probably leads to higher number of drop outs due to adverse events compared with levodopa (moderate certainty).

• Dopamine agonists for the treatment of restless legs syndrome 2011 · Cochrane Headline outcomes only
  OR 1.7
  3 studies · 504 participants
  Moderate

Dopamine agonist vs levodopa

Summary of findings: dopamine agonists showed no clear difference in clinical Global Impressions ‐ Improvement of condition (CGI‐I)… compared with levodopa (moderate certainty).

• Dopamine agonists for the treatment of restless legs syndrome 2011 · Cochrane Headline outcomes only
  RR 1.19 [0.91, 1.56]
  2 studies · 422 participants
  Moderate

Dopamine agonist vs levodopa

• Dopamine agonists for the treatment of restless legs syndrome 2011 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 344 participants
  Low

Dopamine agonist vs levodopa

• Dopamine agonists for the treatment of restless legs syndrome 2011 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 314 participants
  Moderate

Dopamine agonist vs levodopa

Summary of findings: dopamine agonists showed no clear difference in number of patients experiencing adverse events compared with levodopa (moderate certainty).

• Dopamine agonists for the treatment of restless legs syndrome 2011 · Cochrane Headline outcomes only
  OR 2.87 [0.43, 19]
  3 studies · 461 participants
  Moderate

Dopamine agonist vs placebo

• Dopamine agonists for the treatment of restless legs syndrome 2011 · Cochrane Headline outcomes only
  no estimate extracted
  15 studies · 1141 participants
  Moderate

Dopamine agonist vs placebo

• Dopamine agonists for the treatment of restless legs syndrome 2011 · Cochrane Headline outcomes only
  no estimate extracted
  11 studies · 677 participants
  High

Dopamine agonist vs placebo

Summary of findings: dopamine agonists leads to higher number of dropouts due to adverse events compared with placebo (high certainty).

• Dopamine agonists for the treatment of restless legs syndrome 2011 · Cochrane Headline outcomes only
  OR 1.82 [1.35, 2.45]
  34 studies · 7054 participants
  High

Dopamine agonist vs placebo

Summary of findings: dopamine agonists leads to higher clinical Global Impressions ‐ Improvement of condition (CGI‐I)… compared with placebo (high certainty).

• Dopamine agonists for the treatment of restless legs syndrome 2011 · Cochrane Headline outcomes only
  RR 1.44 [1.34, 1.54]
  27 studies · 6338 participants
  High

Dopamine agonist vs placebo

• Dopamine agonists for the treatment of restless legs syndrome 2011 · Cochrane Headline outcomes only
  no estimate extracted
  22 studies · 4592 participants
  High

Dopamine agonist vs placebo

• Dopamine agonists for the treatment of restless legs syndrome 2011 · Cochrane Headline outcomes only
  no estimate extracted
  17 studies · 4312 participants
  Moderate

Dopamine agonist vs levodopa

• Dopamine agonists for the treatment of restless legs syndrome 2011 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 383 participants
  Moderate